GRAL NASDAQ
GRAIL, Inc.
1W: +9.8%
1M: +29.0%
3M: +35.1%
YTD: -23.6%
1Y: +72.6%
$67.19
-0.67 (-0.99%)
After Hours: $65.37 (-1.82, -2.72%)
Weekly Expected Move ±11.3%
$46
$53
$60
$66
$73
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.9B
52W Range29.95-118.84
Volume410,623
Avg Volume969,070
Beta3.04
Dividend—
Analyst Ratings
Company Info
CEORobert Ragusa
Employees1,000
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2024-06-12
Websitegrail.com
1525 OâBrien Drive
Menlo Park, CA 94025
US
Menlo Park, CA 94025
US
833-694-2553
About GRAIL, Inc.
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
Latest News
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| MIZELL STEVEN | A-Award | 396 | $49.79 | 2026-04-15 |
| CHASE WILLIAM J | A-Award | 408 | $49.79 | 2026-04-15 |
| SUMME GREGORY L | A-Award | 631 | $49.79 | 2026-04-15 |
| Freidin Aaron | S-Sale | 45,806 | $49.92 | 2026-04-08 |
| RAGUSA ROBERT P | S-Sale | 123,502 | $49.92 | 2026-04-08 |